The global antisense and RNAi therapeutics market size is expected to reach USD 14.35 billion by 2030, registering a CAGR of 18.72% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.
Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.
Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.
Request a free sample copy or view report summary: Antisense And RNAi Therapeutics Market Report
Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.
The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.
Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.
North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.
Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.
Grand View Research has segmented the global antisense and RNAi therapeutics market report based on technology, application, route of administration, and region
Antisense And RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2018 - 2030)
Antisense And RNAi Therapeutics Application Outlook (Revenue, USD Million, 2018 - 2030)
Cardiometabolic & Renal Disorders
Antisense And RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Other Delivery Methods
Antisense And RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
List of Key Players of Antisense And RNAi Therapeutics Market
Olix Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Benitec Biopharma Inc.
Ionis Pharmaceuticals, Inc
Percheron Therapeutics Limited
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."